These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 28740376

  • 1. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
    Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, McAulay K, Mersmann S, Dalvi PS, Overend T.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1961-1971. PubMed ID: 28740376
    [Abstract] [Full Text] [Related]

  • 2. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M.
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [Abstract] [Full Text] [Related]

  • 5. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.
    Respir Res; 2017 May 30; 18(1):106. PubMed ID: 28558833
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE.
    Drugs; 2009 May 30; 69(5):549-65. PubMed ID: 19368417
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 30; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C, Naya I, Ekelund J.
    Clin Drug Investig; 2012 Jul 01; 32(7):439-49. PubMed ID: 22607479
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 01; 12():339-349. PubMed ID: 28176893
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J, Baldi S, Zhao L, Li H, Lee KH, Singh D, Papi A, Grapin F, Guasconi A, Georges G.
    Respir Res; 2021 Mar 23; 22(1):90. PubMed ID: 33757520
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr 23; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 16. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr 23; 10():201-9. PubMed ID: 25670896
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.